Insulin glargine and cancer: A storm in a glass of water?;Insuline glargine et cancer: Une tempête dans un verre d'eau?

Revue Medicale de Liege

Volumn 64, Issue 9, 2009, Pages 440-445

  Scheen, A J ^a   Lefebvre, P J ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Cancer; Insulin analogues; Insulin glargine; Observational studies

Indexed keywords

INSULIN GLARGINE;

CANCER INCIDENCE; CANCER RISK; HAZARD RATIO; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; NEOPLASMS; RISK;

EID: 70349442489     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Numéro spécial.- Le diabète sucré dans tous ses états. Rev Med Liège, 2005, 60, 269-631 (accessible online sur le site : http://www.rmlg.ulg.ac.be).
2. Radermecker RP.- Le risque hypoglycémique chez le patient diabétique : implications thérapeutiques. Rev Med Liège, 2005, 60, 461-465.
3. Oiknine R, Bernbaum M, Mooradian AD.- A critical appraisal of the role of insulin analogues in the management of diabetes mellitus. Drugs, 2005, 65, 325-340.
4. Dunn CJ, Plosker GL, Keating GM, et al.- Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs, 2003, 63, 1743-1778.
5. Scheen AJ.- Insuline glargine (Lantus®). Rev Med Liège, 2004, 59, 110-114.
6. Nathan DM, Buse JB, Davidson MB, et al.- Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2009, 52, 17-30.
7. Smith U, Gale EAM.- Does diabetes therapy influence the risk of cancer ? Diabetologia, 2009, 52, 1699-1708.
8. Lefèbvre P.- Insulin and cancer : Should one worry ? Arch Physiol Bioch, 2008, 114, 1-2.
9. Hemkens LG, Grouven U, Bender R, et al.- Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia, 2009, 52, 1732-1744.
10. Jonasson JM, Ljung R, Talbäck M, et al.- Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia, 2009, 52, 1745-1754.
11. Currie CJ, Poole CD, Gale EA.- The influence of glucose- lowering therapies on cancer risk in type 2 diabetes. Diabetologia, 2009, 52, 1766-1777.
12. Colhoun HM, SDRN Epidemiology Group.- Use of insulin glargine and cancer incidence in Scotland : a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia, 2009, 52, 1755-1765.
13. Rosenstock J, Fonseca V, McGill JB, et al.- Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes : a long-term, randomised, open-label study. Diabetologia, 2009, 52, 1778-1788.
14. Rosenstock J, Fonseca V, Mc Gill JB, et al.- Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia, 2009, 52, 1971-1973.
15. Le Roith D.- Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes. Diabetes Metab Res Rev, 2009, 23, 593-599.
16. Garg SK, Hirsch IB, Skyler JS.- Insulin glargine and cancer-An unsubstantiated allegation. Diabetes Technol Ther, 2009, 11, 473-476.
17. Pocock SJ, Smeeth L.- Insulin glargine and malignancy : an unwarranted alarm (comment). Lancet, 2009, 52, 511-513.
18. Numéros spéciaux.- De la médecine factuelle aux recommandations thérapeutiques. Rev Med Liège, 2000, 55, 201-477.
19. Gale EAM.- Insulin glargine and cancer : another side to the story ? (letter) Lancet, 2009, 374, 521.
20. Scheen AJ.- De la plus-value thérapeutique au surcoût d'un nouveau médicament : à propos d'un hiatus croissant. Rev Med Suisse, 2005, 1, 1931-1932.
21. Tuffs A.- German agency suspects that insulin analogue glargine increases risk of cancer. BMJ, 2009, 339, b2774.
22. Friis S, Olsen JH.- Statin use and cancer risk: an epidemiologic review. Cancer Invest, 2006, 24, 413-424.
23. Scheen AJ.- Rosiglitazone : to be or not to be ? Diabetologia, 2009, 52, 1448-1450.
24. Scheen AJ, Lefèbvre PJ.- Le traitement pharmacologique du diabète de type 2 est-il maudit ? Méd Hyg, 1998, 56, 1539-1540.
25. Scheen AJ.- Exenatide once weekly in type 2 diabetes. Lancet, 2008, 372, 1197-1198.